De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trialXiuchun Chen, Zhenzhen Liu, Min Yan et al.|The Lancet Oncology|2024Cited by 32
Utidelone Plus Bevacizumab for <i>ERBB2</i>-Negative Metastatic Breast Cancer and Active Brain MetastasesMin Yan, Rongguo Qiu, Huimin Lv et al.|JAMA Oncology|2025Cited by 4